XML 19 R44.htm IDEA: XBRL DOCUMENT v3.20.1
SEGMENT INFORMATION (Tables)
 6 Months Ended
Apr. 30, 2020
Segment Reporting [Abstract]  
Segment Profitability and Segment Assets
The following table reflects segment assets under our management reporting system. Segment assets include allocations of corporate assets, goodwill, net other intangibles and other assets. Unallocated assets primarily consist of cash, cash equivalents, the valuation allowance relating to deferred tax assets and other assets.  
 
April 30,
2020
 
October 31,
2019
 
(in millions)
Segment Assets:
 
 
 
Life Sciences and Applied Markets
$
3,112

 
$
3,202

Diagnostics and Genomics
2,515

 
2,620

Agilent CrossLab
1,343

 
1,331

Total segment assets
$
6,970

 
$
7,153


The profitability of each of the segments is measured after excluding transformational initiatives, acquisition and integration costs, investment gains and losses, interest income, interest expense, acquisition and integration costs, non-cash amortization and other items as noted in the reconciliations below:
 
Three Months Ended
 
Six Months Ended
 
April 30,
 
April 30,
 
2020
 
2019
 
2020
 
2019
 
(in millions)
Net Revenue:
 
 
 
 
 
 
 
Life Sciences and Applied Markets
$
526

 
$
529

 
$
1,164

 
$
1,136

Diagnostics and Genomics
263

 
254

 
512

 
489

Agilent CrossLab
449

 
455

 
919

 
897

Total net revenue
$
1,238

 
$
1,238

 
$
2,595

 
$
2,522

 
 
 
 
 
 
 
 
Segment Income From Operations:


 


 
 
 
 
Life Sciences and Applied Markets
$
98

 
$
107

 
$
256

 
$
266

Diagnostics and Genomics
57

 
49

 
91

 
82

Agilent CrossLab
122

 
115

 
241

 
220

Total segment income from operations
$
277

 
$
271

 
$
588

 
$
568
Reconciliation of segment results to total enterprise results
The following table reconciles reportable segments’ income from operations to Agilent’s total enterprise income before taxes: 
 
Three Months Ended
 
Six Months Ended
 
April 30,
 
April 30,
 
2020
 
2019
 
2020
 
2019
 
(in millions)
Total reportable segments’ income from operations
$
277

 
$
271

 
$
588

 
$
568

Transformational initiatives
(15
)
 
(9
)
 
(28
)
 
(14
)
Amortization of intangible assets related to business combinations
(46
)
 
(26
)
 
(94
)
 
(54
)
Acquisition and integration costs
(11
)
 
(10
)
 
(24
)
 
(20
)
Asset impairment
(99
)
 
—

 
(99
)
 
—

NASD site costs
—

 
(4
)
 
—

 
(6
)
Special compliance costs
—

 
(1
)
 
—

 
(1
)
Other(1)
(4
)
 
(5
)
 
(26
)
 
(7
)
Interest income
3

 
10

 
6

 
20

Interest expense
(20
)
 
(17
)
 
(40
)
 
(35
)
Other income (expense), net (2)
36

 
9

 
57

 
15

Income before taxes, as reported
$
121

 
$
218

 
$
340

 
$
466


(1) The other category primarily includes the legal costs related to a claim we pursued against Twist Bioscience Corporation
in addition to other miscellaneous adjustments.
(2) Other income (expense), net includes the settlement of the legal claim against Twist Bioscience Corporation.